Drug Information

Drug General Information
Drug ID
D0B3GF
Former ID
DNCL002133
Drug Name
JNJ-26854165
Drug Type
Small molecular drug
Indication Non-small cell lung cancer; Prostate cancer [ICD9: 185; ICD10:C33-C34, C61] Phase 1 [522321]
Company
Johnson & Johnson Pharmaceutical
Structure
Download
2D MOL

3D MOL
Formula
C21H20N4
Canonical SMILES
C1=CC=C2C(=C1)C(=CN2)CCNC3=CC=C(C=C3)NC4=CC=NC=C4
InChI
1S/C21H20N4/c1-2-4-21-20(3-1)16(15-24-21)9-14-23-17-5-7-18(8-6-17)25-19-10-12-22-13-11-19/h1-8,10-13,15,23-24H,9,14H2,(H,22,25)
InChIKey
CEGSUKYESLWKJP-UHFFFAOYSA-N
PubChem Compound ID
11609586
PubChem Substance ID
16712431, 23719842, 80031113, 99437011, 124757051, 125163855, 125570991, 131480679, 135354294, 136367345, 137276015, 141237741, 141452097, 152258348, 160647186, 160834972, 162011792, 162037481, 162202718, 163096850, 163400762, 163845686, 164045297, 164127604, 164194047, 164779935, 174531178, 184815993, 188899564, 198947717, 204364943, 223377653, 223577219, 223705088, 229067315, 242060118, 243276763, 249867804, 250208779, 251963251, 252067977, 252215622, 252440638, 252451764
Target and Pathway
Target(s) Ubiquitin-protein ligase E3 Mdm2 Target Info Modulator [532478]
KEGG Pathway FoxO signaling pathway
Cell cycle
p53 signaling pathway
Ubiquitin mediated proteolysis
Endocytosis
PI3K-Akt signaling pathway
Thyroid hormone signaling pathway
Epstein-Barr virus infection
Pathways in cancer
Transcriptional misregulation in cancer
Viral carcinogenesis
Proteoglycans in cancer
MicroRNAs in cancer
Glioma
Prostate cancer
Melanoma
Bladder cancer
Chronic myeloid leukemia
PANTHER Pathway Insulin/IGF pathway-protein kinase B signaling cascade
p53 pathway
Ubiquitin proteasome pathway
P53 pathway feedback loops 1
p53 pathway feedback loops 2
Pathway Interaction Database ErbB4 signaling events
p73 transcription factor network
ATR signaling pathway
ATM pathway
Glucocorticoid receptor regulatory network
Sumoylation by RanBP2 regulates transcriptional repression
Direct p53 effectors
Regulation of Androgen receptor activity
Validated transcriptional targets of deltaNp63 isoforms
Aurora A signaling
Validated transcriptional targets of TAp63 isoforms
p53 pathway
Regulation of retinoblastoma protein
Reactome AKT phosphorylates targets in the cytosol
Oxidative Stress Induced Senescence
Oncogene Induced Senescence
Trafficking of AMPA receptors
Constitutive Signaling by AKT1 E17K in Cancer
Stabilization of p53
WikiPathways DNA Damage Response (only ATM dependent)
DNA Damage Response
ErbB Signaling Pathway
Senescence and Autophagy in Cancer
Tryptophan metabolism
G1 to S cell cycle control
Copper homeostasis
Bladder Cancer
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
PIP3 activates AKT signaling
Apoptosis
ATM Signaling Pathway
Retinoblastoma (RB) in Cancer
Integrated Pancreatic Cancer Pathway
Prostate Cancer
Signaling Pathways in Glioblastoma
Integrated Breast Cancer Pathway
Integrated Cancer pathway
Cell Cycle
Cell Cycle Checkpoints
TP53 Network
miRNA Regulation of DNA Damage Response
Androgen receptor signaling pathway
References
Ref 522321ClinicalTrials.gov (NCT00676910) A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.. U.S. National Institutes of Health.
Ref 532478Serdemetan antagonizes the Mdm2-HIF1alpha axis leading to decreased levels of glycolytic enzymes. PLoS One. 2013 Sep 6;8(9):e74741.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.